Abstract: The present invention is directed to tablets for oral administration to a subject, comprising a therapeutically effective amount of SYN120 or a pharmaceutically acceptable salt thereof, wherein the tablet is substantially free of lactose. The present invention is also directed to methods for treating diseases or conditions including Alzheimer's disease and/or Parkinson's disease, comprising administering to a patient in need thereof tablets regarding the same.

Abstract: The present invention is directed to tablets for oral administration to a subject, comprising a therapeutically effective amount of SYN120 or a pharmaceutically acceptable salt thereof, wherein the tablet is substantially free of lactose. The present invention is also directed to methods for treating diseases or conditions including Alzheimer's disease and/or Parkinson's disease, comprising administering to a patient in need thereof tablets regarding the same.

Abstract: The present invention provides a controlled-release composition containing tozadenant, at least one cellulose ether, and one or more pharmaceutically acceptable excipients. In the composition, the tozadenant is present in an amount ranging from about 30% (w/w) to about 65% (w/w) based on the total composition weight; and the cellulose ether is present in an amount sufficient to provide: not less than about 10% and not more than about 30% tozadenant dissolution over a 2-hour test period, not less than about 55% tozadenant dissolution over a 10-hour test period, and not less than about 80% tozadenant dissolution over a 16-hour test period. Use of the composition for treatment of Parkinson's disease is also described.

Abstract: The present invention provides a controlled-release composition containing tozadenant, at least one cellulose ether, and one or more pharmaceutically acceptable excipients. In the composition, the tozadenant is present in an amount ranging from about 30% (w/w) to about 65% (w/w) based on the total composition weight; and the cellulose ether is present in an amount sufficient to provide: not less than about 10% and not more than about 30% tozadenant dissolution over a 2-hour test period, not less than about 55% tozadenant dissolution over a 10-hour test period, and not less than about 80% tozadenant dissolution over a 16-hour test period. Use of the composition for treatment of Parkinson's disease is also described.

Abstract: The present invention is directed to tablets for oral administration to a subject, comprising a therapeutically effective amount of SYN120 or a pharmaceutically acceptable salt thereof, wherein the tablet is substantially free of lactose. The present invention is also directed to methods for treating diseases or conditions including Alzheimer's disease and/or Parkinson's disease, comprising administering to a patient in need thereof tablets regarding the same.

Abstract: The present invention is directed to tablets for oral administration to a subject, comprising a therapeutically effective amount of SYN120 or a pharmaceutically acceptable salt thereof, wherein the tablet is substantially free of lactose. The present invention is also directed to methods for treating diseases or conditions including Alzheimer's disease and/or Parkinson's disease, comprising administering to a patient in need thereof tablets regarding the same.

Abstract: The present invention is directed to tablets for oral administration to a subject, comprising a therapeutically effective amount of SYN120 or a pharmaceutically acceptable salt thereof, wherein the tablet is substantially free of lactose. The present invention is also directed to methods for treating diseases or conditions including Alzheimer's disease and/or Parkinson's disease, comprising administering to a patient in need thereof tablets regarding the same.

Abstract: The present invention provides topical formulations containing a vitamin K analog, e.g., menadione, that deliver a uniform, therapeutically effective concentration of the vitamin K analog to the skin in a vehicle which is stable, non-irritating, non-drying and cosmetically acceptable. These topical formulations are useful for the treatment and prevention of dermatological conditions associated with inflammation, particularly, dermatological conditions resulting from anti-EGFR therapies.

Abstract: The present invention provides topical formulations containing a vitamin K analog, e.g., menadione, that deliver a uniform, therapeutically effective concentration of the vitamin K analog to the skin in a vehicle which is stable, non-irritating, non-drying and cosmetically acceptable. These topical formulations are useful for the treatment and prevention of dermatological conditions associated with inflammation, particularly, dermatological conditions resulting from anti-EGFR therapies.

Abstract: The present invention provides topical formulations containing a vitamin K analog, e.g., menadione, that deliver a uniform, therapeutically effective concentration of the vitamin K analog to the skin in a vehicle which is stable, non-irritating, non-drying and cosmetically acceptable. These topical formulations are useful for the treatment and prevention of dermatological conditions associated with inflammation, particularly, dermatological conditions resulting from anti-EGFR therapies.

Abstract: A composition for use as a sunscreen applied during washing includes photoprotective agents of the organic type (e.g., octylmethoxy cinnamate and oxybenzone), the inorganic type (e.g., titanium dioxide and zinc oxide), or combinations of the organic and inorganic agents. Additional components include skin penetration enhancers, emollients and surfactants. Additional sunscreen combinations include a sunscreen cleanser based upon triethanolamine (TEA).

Abstract: It has been found that a lubricating oil containing: (1) an alkali metal borate; (2) an oil-soluble sulfur compound; (3) a dialkyl hydrogen phosphite; and (4) a mixture of neutralized phosphates said phosphates being essentially free of monothiophosphates interacts synergistically to provide a lubricant with superior load carrying properties.

Abstract: Disclosed is the compound trihydrated potassium triborate having the following chemical formula: KB.sub.3 O.sub.5.3H.sub.2 O. Also disclosed is a process for the production of trihydrated potassium triborate by reacting potassium pentaborate tetrahydrate with either dipotassium tetraborate tetrahydrate or with dipotassium pentaborate pentahydrate by contacting the two solid reactants under reaction conditions including an amount of water sufficient to cause reaction and insufficient to dissolve the two reactant solids. The new trihydrated potassium triborate may also be prepared by treating dipotassium pentaborate pentahydrate with water under the same reaction conditions.

Abstract: Disclosed is a lubricating oil additive comprising a mixture of phosphates, said phosphates being essentially free of monothiophosphates and comprising:(a) dihydrocarbyl hydrogen dithiophosphates; and(b) a sulfur-free mixture of hydrocarbyl dihydrogen phosphates and dihydrocarbyl hydrogen phosphates, said composition being at least 50% neutralized by a hydrocarbyl amine having 10 to 30 carbons in said hydrocarbyl group.

Abstract: Disclosed is a lubricating composition comprising an oil of lubricating viscosity having dispersed therein a minor amount of an additive composition comprising a mixture of: (a) a hydrated alkali metal borate; (b) an oil-soluble sulfur-containing compound; and (c) a zirconium salt.

Abstract: Disclosed is an alkali-metal borate containing lubricant which also contains a phosphate, monothiophosphate and dithiophosphate in a critical ratio.

Abstract: Disclosed is a lubricant composition containing an oil of lubricating viscosity having dispersed therein a particulate hydrated alkali-metal borate and an effective amount of a sulfur-containing polyhydroxy compound which stabilizes the composition against the adverse effects of water contamination.